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Introduction
Tocilizumab was recommended for the treatment of
systemic juvenile idiopathic arthritis (sJIA) in children
whose disease has responded inadequately to non-steroidal
anti-inflammatory drugs, systemic corticosteroids and
methotrexate.
Objectives
To study the efficacy and tolerability of Tocilizumab
(TCZ) in patients with longstanding refractory to the
conventional treatment and TNF-inhibitors sJIA.
Methods
Seven children in the age range 2-12 years (mean 6.3
years) with disease duration 1.2 - 9 years (mean 4.6 years)
with active persistent sJIA have been enrolled in one-year
prospective study. All 7 patients had oligoarticular joint
involvement and received previous treatment with
NSAIDS, Methotrexate and corticosteroids. 4/7 had con-
comitant therapy with Etanercept and 2/7 second
DMARD. In all patients TCZ was administered immedi-
ately after discontinuation of the biological treatment or
the second DMARD in a dose of 8 mg/kg for patients ≥
30 kg and 12 mg/kg for patients < 30 kg every two weeks.
At baseline all patients had active disease. Response to
the treatment was measured according to the ACR Pedi
criteria at the end of the 1st, 3rd, 6th, 9th and 12th month.
Clinical examination, laboratory investigations, growth
parameters’ assessment and screening for adverse events
have been performed every 2 weeks.
Results
At the end of the 1st month we found complete resolu-
tion of the systemic symptoms and acute phase response
in all patients. At the end of the 3rd month, ACR Pedi
30, 50, 70 and 90 responses were achieved by 7 (100%),
5 (71%), 1(14%) and 0 (0%) patients, respectively. By 6th
month the observed responses we as follows: ACR Pedi
30 - 7 pts (100%), ACR Pedi 50 - 7 pts (100%), ACR
Pedi 70 - 5 pts (71%), ACR 90 - 1 patient (14%). At the
end of 9th month ACR Pedi 30, 50, 70 and 90 responses
were achieved by 7 (100%), 7 (100%), 6 (86%) and
4 (57%) patients. All patients maintained these para-
meters by 12th month.
After achieving control of the disease activity, we
started to reduce the dose of steroids and/or Methotrex-
ate leading to their discontinuation and monotherapy
with TCZ in 4 patients. In all of these patients remission
on medication was documented by 12th month. At the
end of the observational period the linear growth velo-
city of all treated patients reached the average normal
values per year of their age matched peers.
Some patients experienced mild and reversible adverse
reactions such as: mild neutropenia or thrombocytope-
nia, slight increase of liver enzymes and increased cho-
lesterol levels. All side effects resolved with the decrease
of the dosage and did not lead to the discontinuation of
the treatment.
Conclusion
Tocilizumab is an effective and well tolerated drug in
children with systemic longstanding persistent JIA, refrac-
tory to the conventional treatment and TNF-inhibition.
Monotherapy with TCZ is an appropriate option for con-
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